On April 29th 2009, the World Health Organization (WHO) announced that the rapid global spread of a new swine origin strain of influenza A (H1N1) virus (A/California/04/2009 (H1N1), A/California/06/2009 (H1N1), A/California/07/2009 (H1N1)) detected in the previous week warranted moving the global flu pandemic alert level to phase 5. Phase 5 indicates sustained human-to-human transmission of a novel influenza strain of animal origin in one WHO region of the world, and exported cases detected in other regions. Since its outbreak, the new swine influenza H1N1 virus has infected millions of people worldwide and thousands of death. This new influenza outbreak is commonly referred to as the 2009 swine flu pandemic.
Sino Biological Inc reacted quickly to the Swine Influenza Pandemic threat. Recombinant Hemagglutinin Protein from the Swine Influenza Virus Strain A/California/04/2009 (H1N1) was produced on May 17, 2009, only 20 days after the publication of the swine flu gene sequence. Since then we have generated rabbit polyclonal antibodies, mouse and rabbit monoclonal antibodies to the swine Influenza H1N1 Hemagglutinin protein. Some of the monoclonal antibodies have very high specificity to the swine influenza H1N1 virus strain, and have no cross-reactivity to seasonal influenza H1N1, H3N2, B viruses, or the avian influenzau H5N1 viruses.
High affinity monoclonal antibodies to the swine influenza H1N1 virus were used to develop an ELISA assay kits. To date, high sensitivity antibody pair (Duoset) with a detection limit of 5pg/well have been obtained and can be used for the swine influenza H1N1 virus diagnosis and ELISA assay. The panel of antibodies we have obtained can be utilized for swine influenza H1N1 virus detection, ELISA assay, Western Blotting (WB), Flow Cytometry, IHC, etc.